Bicycle Therapeutics plc (BCYC)
Nasdaq · Healthcare · Biotechnology
$4.01+18.64%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $281M
- 52-week range
- $3.33 – $9.16
- 52-week change
- −58.93%
- EPS (trailing)
- −$2.73
- Next earnings
- Oct 29, 2026
Fiscal year to Dec 2025
- Revenue
- $72.6M (+105.77%)
- Net income
- −$219M
- Operating margin
- −340.4%
- Diluted EPS
- −$3.16
- Free cash flow
- −$252M
From the company’s annual report on SEC EDGAR.
About Bicycle Therapeutics plc
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas.
Headquarters: Cambridge, United Kingdom · 288 employees · bicycletherapeutics.com